Article Data

  • Views 522
  • Dowloads 113

Original Research

Open Access

Case analysis of fertility-preserving treatment in female patients with malignant ovarian cancer

  • L. Hong1
  • W. Chen1,*,
  • A. Xing1
  • K. Wang1

1Department of Gynecology, Hainan General Hospital, Haikou

2Department of Radiology, Hainan General Hospital, Haikou (China)

DOI: 10.12892/ejgo3872.2018 Vol.39,Issue 2,April 2018 pp.216-220

Published: 10 April 2018

*Corresponding Author(s): W. Chen E-mail: wangshengchendoc@163.com

Abstract

The aim of this study was to evaluate the impacts of fertility-preserving surgery and chemotherapy on the fertility and ovarian functions in malignant ovarian cancer. The clinical data of 52 female patients with malignant ovarian cancer and performed fertility-preserving treatment (FPT) in the present hospital between June 2004 and December 2014 were retrospectively analyzed. The 52 cases included 25 cases of germ cell carcinoma (GCC) (48.07%), 12 cases of epithelial ovarian carcinoma (EOC) (23.07%), and 15 cases of borderline carcinoma (28.84%), among which one case recurred (1.92%) and one died (1.92%). Forty-five cases had normal menstruation after the treatment (86.53%), and 16 cases out of the 27 cases with fertility requirement successfully achieved pregnancy (59.26%). FPT in female patients with malignant ovarian cancer was effective and feasible; although chemotherapy might affect ovarian function, it could also be reversed. Ovarian tumor resection or adnexectomy may be the best way for fertility preserving treatments; however, further investigation is warranted.

Keywords

Ovarian cancer; Fertility-preserving treatment; Surgery; Chemotherapy.

Cite and Share

L. Hong,W. Chen,A. Xing,K. Wang. Case analysis of fertility-preserving treatment in female patients with malignant ovarian cancer. European Journal of Gynaecological Oncology. 2018. 39(2);216-220.

References

[1] Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al.: “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet, 2012, 380, 2095.

[2] Chornokur G., Amankwah E.K., Schildkraut J.M., Phelan C.M.: “Global ovarian cancer health disparities”. Gynecol. Oncol., 2013, 129, 258.

[3] Kurman R.J., Shih IeM.: “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory”. Am. J. Surg. Pathol., 2010, 34, 433.

[4] Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Aghajanian C., Barakat R.R., Chi D.S.: “The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer”. Gynecol. Oncol., 2008, 108, 276.

[5] Fleming G.F., Ronnett B.M., Seidman J., Zaino R.J., Rubin S.C.: “Epithelial ovarian cancer”. In: Barakat R.R., Markman M., Randall M.E., (eds). Principles and practice of gynecologic oncology. Philadelphia: Lippincott Williams & Wilkins, 2009, 763.

[6] Morgan R.J., Alvarez R.D., Armstrong D.K., Burger R.A., Chen L.M., Copeland L., et al.: “Ovarian cancer, version 2.2013”. J. Natl. Compr. Canc. Netw., 2013, 11, 1199.

[7] Feeley K.M., Wells M.: “Precursor lesions of ovarian epithelial malignancy”. Histopathology, 2001, 38, 87.

[8] Colombo N., Peiretti M., Castiglione M.: “Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up”. Ann. Oncol., 2009, 20, 24.

[9] del Carmen M.G., Birrer M., Schorge J.O.: “Carcinosarcoma of the ovary: a review of the literature”. Gynecol. Oncol., 2012, 125, 271.

[10] Brown J., Frumovitz M.: “Mucinous tumors of the ovary: current thoughts on diagnosis and management”. Curr. Oncol. Rep., 2014, 16, 389.

[11] Wei W., Dizon D., Vathipadiekal V., Birrer M.J.: “Ovarian cancer: genomic analysis”. Ann. Oncol., 2013, 24, x7.

[12] Mahajan N.: “Fertility preservation in female cancer patients: An overview”. J. Hum. Reprod. Sci., 2015, 8, 3.

[13] Nishio S., Ushijima K., Fukui A., Fujiyoshi N., Kawano K., Komai K., et al.: “Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary”. J. Obstet. Gynaecol. Res., 2006, 32, 416.

[14] Lee S.J., Schover L.R., Partridge A.H., Patrizio P., Wallace W.H., Hagerty K., et al: “American Society of Clinical Oncology recommendations on fertility preservation in cancer patients”. J. Clin. Oncol., 2006, 24, 2917.

[15] Wright J.D., Shah M., Mathew L., Burke W.M., Culhane J., Goldman N., et al.: “Fertility preservation in young women with epithelial ovarine cancer”. Cancer, 2009, 115, 4118.

[16] du Bois A., Heitz F., Harter P.: “Fertility-sparing surgery in ovarian cancer: a systematic review”. Onkologie, 2013, 36, 436.

[17] Ditto A., Martinelli F., Lorusso D., Haeusler E., Carcangiu M., Raspagliesi F.: “Fertility sparing surgery in early stage epithelial ovarian cancer”. J. Gynecol. Oncol., 2014, 25, 320.

[18] Kajiyama H., Mizuno M., Shibata K., Yamamoto E., Kawai M., Nagasaka T., et al.: “Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2014, 175, 97.

[19] Vasconcelos I., de Sousa Mendes M.: “Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk”. Eur. J. Cancer., 2015, 51, 620.

[20] Kajiyama H., Shibata K., Mizuno M., Umezu T., Suzuki S., Nawa A., et al.: “Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery”. Br. J. Cancer., 2011, 105, 1288.

[21] Donnez J., Munschke A., Berliere M., Pirard C., Jadoul P., Smets M., et al.: “Safety of conservative management and fertility outcome in women with borderline carcinomas of the ovary”. Fertil. Steril., 2003, 79, 1216.

[22] Fotopoulou C., Braicu I., Sehouli J.: “Fertility-sparing surgery in early epithelial ovarian cancer: a viable option?” Obstet. Gynecol. Int., 2012, 2012, 238061.

[23] Makarewicz H., Emerich J., Olszewski J., Klasa-Mazurkiewicz D.: “Pregnancy and delivery after conservative treatment of borderline ovarine tumer with FIGO stage IIIC-a case report”. Ginekol. Pol., 2002, 73, 225.

[24] Oven Ustaalioglu B.B., Bilici A., Kefeli U., Seker M., Salepci T., Unal O., Gumus M.: “A retrospective analysis of women’s chances to become pregnant after completion of chemotherapy: a single center experience”. J. BUON., 2011, 16, 349.

[25] Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Daraï E: “Restaging surgery forwomen with borderline ovarian tumors”. Cancer, 2004, 100, 1145.

[26] Seltzer V., Drukker B.H., Gillespie B.W., Gossfeld L.M., Grigsby P.W., Harvey H.A., et al.: “NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer”. JAMA., 1995, 273, 491.

[27] Billmire D., Vinocur C., Rescorla F., Cushing B., London W., Schlatter M., et al.: “Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study”. J. Pediatric. Surg., 2004, 39, 424.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top